Cannabis research stock Medlab rallies on ASX debut

Doug Pensinger/Getty Images

Shares in Medlab Clinical, which is looking at trials of medical cannabis in NSW, opened higher on its ASX debut today.

The biotech will use some of the $6.17 million from the IPO to research cannabis as a pain relief drug. NSW has taken a lead in approving clinical trials of cannabis.

The 20 cents shares were trading as high as 21 cents on opening.

The Sydney-based early phase drug development company is expanding its research into chronic kidney disease, obesity, depression, anti-ageing and pain management.

Medlab was formed by Sean Hall after he sold his family’s companies Bioceuticals and Hall Drug Technologies to vitamin giant Blackmores in 2012.

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at